Jeremiah McDole, Ph.D. Named Director of Clinical Research and Development at StemGenex®
New position focuses on StemGenex' commitment to safety and efficacy while developing new technology.
LA JOLLA, Calif., March 18, 2014 /PRNewswire/ -- StemGenex®, a leader in adult adipose-derived stem cell therapy, is pleased to announce that Jeremiah McDole, Ph.D. has been named Director of Clinical Research and Development.
"We couldn't be more excited to welcome Jeremiah," said Rita Alexander, President of StemGenex. "Jeremiah brings a multitude of cutting-edge research experience along with neurological and immunological knowledge which will assist with keeping StemGenex at the forefront of providing access to regenerative medicine."
As Director of Clinical Research and Development at StemGenex, Jeremiah is responsible for project planning and operational delivery of clinical programs in conjunction with overall management, administration, and operation of the laboratory. He will also be responsible for management and development of regulatory compliance while striving to maximize the safety and efficacy of treatments. Further, Jeremiah will drive the advancement of current and future techniques.
"I am a strong believer in cellular medicine and its ability to better patients' lives," said Jeremiah McDole. "Recent discoveries have made stem cells a multi-faceted vehicle to produce incredible advances in personalized therapy. To be in this role with a company like StemGenex is very exciting."
Jeremiah is a 2004 graduate of Berea College. In 2009, he earned a Ph.D. in neuroscience from the University of Cincinnati with a focus in neuroimmunology. Through the end of 2012 he continued his education at Washington University in St. Louis School of Medicine as a Postdoctoral Research Associate in the department of Pathology and Immunology.
During his academic science career, Jeremiah worked in a broad range of therapeutic areas that targeted multiple human diseases. He has publications related to several disease conditions including multiple sclerosis, encephalitis, stroke, and inflammatory bowel disease.
To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email [email protected].
Photo - http://photos.prnewswire.com/prnh/20140318/LA85529
SOURCE StemGenex
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article